EP0666729A1 - Cosmetic composition - Google Patents

Cosmetic composition

Info

Publication number
EP0666729A1
EP0666729A1 EP93923626A EP93923626A EP0666729A1 EP 0666729 A1 EP0666729 A1 EP 0666729A1 EP 93923626 A EP93923626 A EP 93923626A EP 93923626 A EP93923626 A EP 93923626A EP 0666729 A1 EP0666729 A1 EP 0666729A1
Authority
EP
European Patent Office
Prior art keywords
arginine
metabolic intermediate
derivatives
hair
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93923626A
Other languages
German (de)
French (fr)
Inventor
Walter Thomas Gibson
George Terence Evelyn Kealey
Gillian Elizabeth 7 The Sidings Westgate
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever PLC
Unilever NV
Original Assignee
Unilever PLC
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever PLC, Unilever NV filed Critical Unilever PLC
Publication of EP0666729A1 publication Critical patent/EP0666729A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof

Definitions

  • the invention relates to a cosmetic composition for topical application to mammalian skin or hair for increasing or at least maintaining hair growth, especially terminal hair growth on the human scalp.
  • the hair growth cycle can be divided into three main stages, namely: i) an active stage known as anagen, during which the hair follicle penetrates deep into the dermis with the cells of the bulb dividing rapidly and differentiating to form the hair,
  • a regressive stage known as catagen which is heralded by the cessation of mitosis, and during which the follicle regresses upwards through the dermis and hair growth ceases, and
  • telogen a resting stage known as telogen, in which the regressed follicle contains a small secondary germ with an underlying ball of tightly packed dermal papilla cells.
  • citrulline which condenses with aspartate to form argininosuccinate, may also regulate the steps of arginine/urea synthesis by its availability, which would depend on oxaloacetate and in turn TCA cycle intermediates.
  • arginine may also be important for the availability of arginine.
  • RNA and protein biosynthesis due to its being an essential amino acid.
  • the significance of ornithine may be due to its role in the generation of arginine in the follicle rather than to urea.
  • fumarate is produced which can feed into the TCA cycle and contribute to anaplerotic reactions.
  • ithout ornithine and arginine the ammonia which results from a surplus of nitrogen caused by glutaminolysis may rise to toxic levels and prove fatal to cell function due its inhibition of transaminase reactions and hyperglutaminaemia.
  • the invention is accordingly concerned with the use of these intermediates in hair follicle metabolism, so as to increase or maintain hair growth.
  • the invention provides a composition which is suitable for topical application to mammalian skin or hair for increasing, enhancing or maintaining hair growth, which composition comprises: i) an effective amount of a metabolic intermediate of the urea cycle chosen from arginine, ornithine, citrulline, argininosuccinate, their salts, hydrosalts and precursors thereof, and mixtures thereof; and ii) a cosmetically acceptable vehicle for the intermediate.
  • a metabolic intermediate of the urea cycle chosen from arginine, ornithine, citrulline, argininosuccinate, their salts, hydrosalts and precursors thereof, and mixtures thereof.
  • the invention provides a method of increasing, enhancing or maintaining hair growth by use of such a composition. Use is by topical application especially to the bald or balding human scalp.
  • the invention is concerned with the utilisation of a metabolic intermediate which is part of the urea cycle, or a derivative of such a metabolic intermediate, and its topical application for the purposes of increasing or maintaining hair growth, particularly on the human scalp.
  • a metabolic intermediate which is part of the urea cycle, or a derivative of such a metabolic intermediate, and its topical application for the purposes of increasing or maintaining hair growth, particularly on the human scalp.
  • SUBSTITUTE SHEET (TCA) cycle is shown in Figure 1. From this, four metabolic intermediates of the urea cycle, namely arginine, ornithine, citrulline and argininosuccinate have been selected as possessing the ability to promote linear hair growth to an extent which is significantly greater than glutamine itself.
  • Each of these four metabolic intermediates can therefore incorporated into a composition for topical application to skin or hair, in particular the scalp, for promoting or at least maintaining hair growth.
  • a particularly preferred example of a salt is the sodium salt, and a preferred example of a hydro salt is a hydrohalide especially the hyrochloride derivatives of these intermediates.
  • R 1 is chosen from:
  • amino acid residues or substituted amino acid residues as herein defined, being derived from one or more of the following amino acids:
  • DOPA L-3,4-dihydroxyphenylalanine
  • alkali metal cations chosen from Na + and K + , (i ⁇ ) NH 4 + or alkanolam onium ions, and
  • x is a integer of from 1 to 22, and y is an integer of from 3 to 45;
  • hydrohalide derivatives of urea cycle intermediates are:
  • alkali metal salt derivatives of urea cycle intermediates are:
  • dipeptide derivatives of urea cycle intermediates are:
  • composition can comprise two or more urea cycle intermediates or derivatives thereof, as herein defined.
  • the chosen urea cycle intermediate is citrulline, or a derivative thereof
  • it is preferably to include aspartate in the composition according to the invention, in view of the combination of citrulline and aspartate to from arginosuccinate, as is evident from Figure 1.
  • carbamoyl phosphate when the chosen urea cycle intermediate is ornithine, or a derivative thereof, it is advantageous to include carbamoyl phosphate in the composition accordingly to the invention, as carbamoyl phosphate promotes the formulation of citrulline from ornithine, as can also be seen from Figure 1.
  • the total amount of the urea cycle intermediate or derivative thereof present in the composition according to the invention is an amount which is sufficient to induce maintain or increase hair growth. This amount will depend on the effectiveness of the intermediate, some being more effective than others, but in general an amount of from 0.001 to 99%, usually from 0.01 to 30% by weight of the composition will provide an adequate concentration for application to the skin, particularly the scalp, which can then be repeated as necessary to promote hair growth.
  • composition according to the invention also comprises a solid, semi-solid or liquid cosmetically and/or physiologically acceptable vehicle, to enable the urea cycle intermediate, or derivative thereof, to be conveyed to the skin at an appropriate dilution.
  • vehicle will depend upon the method chosen for topical administration of the composition.
  • the vehicle can itself be inert or it can possess physiological or pharmaceutical benefits of its own.
  • a vehicle for this purpose presents a wide range of possibilities depending on the required product form of the composition. Suitable vehicles can be classified as described hereinafter.
  • vehicles are substances which can act as diluents, dispersants, or solvents for the urea cycle intermediate, or derivative thereof, which therefore ensure that they can be applied to and distributed evenly over the hair and/or scalp at an appropriate concentration.
  • the vehicle is preferably one which can aid penetration of the esters into the skin to reach the immediate environment of the hair follicle, compositions according to the invention can include water as a vehicle, and/or at least one cosmetically acceptable vehicle other than water.
  • Vehicles other than water can include liquid or solid emollients, solvents, humectants, thickeners and powders. Examples of each of these types of vehicle, which can be used singly or as mixtures of one or more vehicles, are as follows:
  • Emollients such as stearyl alcohol, glyceryl monoricinoleate, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, eicosanyl alcohol, behenyl alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, cocoa butter, corn oil, cotton seed oil, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, evening primrose oil, soybean oil,
  • Propellants such as propane, butane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide;
  • Solvents such as ethyl alcohol., methylene chloride, isopropanol, acetone, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxid ⁇ , dimethyl formamide, tetrahydrofuran;
  • Powders such as chalk, talc, fullers earth, kaolin, starch, gums, colloidal silica sodium polyacrylate, tetra alkyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate, ethylene glycol distearate;
  • the cosmetically acceptable vehicle will usually form from 10 to 99.999%, preferably from 10 to 99% and most preferably from 50 to 99% by weight of the emulsion, and can, in the absence of other cosmetic adjuncts, form the balance of the composition.
  • composition according to the invention can also optionally comprise an activity enhancer.
  • the activity enhancer can be chosen from a wide variety of molecules which can function in different ways to enhance the hair growth effects of the urea cycle intermediate.
  • Particular classes of activity enhancers include (a) other hair growth stimulants, (b) penetration enhancers and (c) cationic polymers, whose presence can further improve the delivery of the ester through the stratum corneum to its site of action in the immediate environment of the hair follicle.
  • Some activity enhancers can also function as vehicles for the ester. .a. Other Hair Growth Stimulants
  • Glycosaminoglycanase inhibitors as described by Unilever in EP 0 277 428, such as D-Glucaro-1,4- lactone.
  • Glycosaminoglycanase inhibitors as described by Unilever in EP 0 277 428, such as N- acetylglucosamine.
  • x. Glycosa inoglycan chain cellular uptake inhibitors as described by Unilever in EP 0 277 428, such as hexuronic acid and esters thereof.
  • Glycosaminoglycanase inhibitors as described by Unilever in EP 0 348 184, chosen from acylated monosaccharides , such as 2-propionamido-2- deoxyglucose.
  • esters of pyroglutamic acid as described by Lever Brothers Company in US 4 774 255, such as pyroglutamic acid ,n-hexyl ester and pyroglutamic acid n-octyl ester.
  • a penetration enhancer can potentiate the benefit of the urea cycle intermediate or derivative thereof by improving its delivery through the stratum corneum to its site of action in the hair follicle.
  • the penetration enhancer can accordingly function in a variety of ways. It can for example, improve the distribution of the urea cycle intermediate on the skin surface or, it can increase its partition into the skin from the composition when applied topically, so aiding its passage to its site of action. Other mechanisms enhancing the benefit of the hair growth promoter may also be involved.
  • penetration enhancers examples include:
  • a cationic polymer can potentiate the benefit of the urea cycle intermediate or derivative thereof by improving its delivery to the hair and scalp.
  • preferred cationic polymers include:
  • Quaternised poly dimethylaminoethylmethacrylate
  • the amount of activity enhancer when employed in accordance with the invention, will normally be from 0.1 to 50%, preferably from 0.5 to 25% and most preferably from 0.5 to 10% by weight of the composition.
  • composition according to the invention is an emulsion, in which case an oil or oily material will normally be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion, depending largely on the average hydrophilic-lyophilic balance (HLB) of the emulsifier employed.
  • HLB hydrophilic-lyophilic balance
  • composition according to the invention can optionally comprise one or more oils or other materials having the properties of an oil.
  • oils examples include mineral oil and vegetable oils, and oil materials, such as those already proposed herein as emollients.
  • oils or oily materials include silicone oils, both volatile and non- volatile, such as polydimethyl siloxanes.
  • the oil or oily material when present for . the purposes for forming an emulsion, will normally form up to 90%, preferably from 10 to 80% by volume of the composition.
  • composition according to the invention can also optionally comprise one or more emulsifiers the choice of which will normally determine whether a water-in-oil or and oil-in-water emulsion is formed.
  • the chosen emulsifier or emulsifiers should normally have an average HLB value of from 1 to 6.
  • a chosen emulsifier or emulsifiers should have an average HLB value of >6.
  • Suitable emulsifiers are set below in Table 1 in which the chemical name of the emulsifiers is given together with an example of a trade name as commercially available, and the average HLB value.
  • Sorbitan trioleate Sorbitan tristearate Glycerol monooleate Glycerol monostearate Glycerol monolaurate Sorbitan sesquioleate Sorbitan monooleate Sorbitan monostearate Poloxyethylene (2) stearyl ether Poloxyethylene sorbitol beeswax derivative PEG 200 dilaurate Sorbitan monopalraitate Polyoxyethylene (3.5) nonyl phenol PEG 200 monostearate
  • the amount of emulsifier or mixtures thereof, to be incorporated in the composition of the invention, when appropriate is from 1 to 50%, preferably from 2 to 20% and most preferably from 2 to 10% by weight of the composition.
  • composition of the invention can also comprise water, usually up to 90%, preferably from 5 to 80% by volume. Water can function as the cosmetically acceptable vehicle.
  • composition of the invention can also optionally comprise a high molecular weight silicone surfactant which can also act as an emulsifier, in place of or in addition to the optional emulsifier(s) already mentioned.
  • a high molecular weight silicone surfactant which can also act as an emulsifier, in place of or in addition to the optional emulsifier(s) already mentioned.
  • the silicone surfactant is a high molecular weight polymer of dimethyl polysiloxane with polyoxyethylene and/or polyoxypropylene side chains having a molecular weight from 10,000 to 50,000.
  • the dimethyl polysiloxane polymer is conveniently provided as a dispersion in a volatile siloxane, the dispersion comprising, for example, from 1 to 20% by volume of the polymer and from 80 to 99% by volume of the volatile siloxane.
  • the dispersion consists of a 10% by volume of the polymer dispersed in the volatile siloxane.
  • Examples of the volatile siloxanes in which the polysiloxane polymer can be dispersed include polydimethyl siloxane (pentamer and/or hexamer) .
  • a particularly preferred silicone surfactant is cyclomethicone and dimethicone copolyol, such as DC 3225C
  • Formulation Aid available from DOW CORNING. Another is laurylmethicone copolyol, such as DC Q2-5200, also available from Dow Corning.
  • the amount of silicone surfactant, when present in the composition will normally be up to 25%, preferably from 0.5 to 15% by weight of the emulsion.
  • composition for use in the method according to the invention can be formulated as a shampoo and will then accordingly comprise one or more surfactants which are cosmetically acceptable and suitable for topical application to the hair.
  • suitable shampoo surfactants are given below.
  • a composition is formulated to contain surfactant in a quantity of 4% by weight or more, it may prove desirable to use the metabolic intermediate in a concentration of more than 5% by weight, possibly more than 8% by weight. This may even prove desirable when surfactant is present in lower concentrations, such as 1% by weight or more.
  • composition of the invention can comprise an anionic surfactant which is preferably chosen from alkyl sulphate, alkyl ether sulphate, alkyl sulphonate, alkyl aryl sulphonate, olefin sulphonate, acyl sarcosinate, acyl tauride, acyl isethionate, nonoalkyl sulphosuccinate, dialkylsulphosuccinate, acryl lactylate, acylated ⁇ -amino acid, alkyl carboxylate, monoalkyl phosphate and dialkyl phosphate.
  • anionic surfactant which is preferably chosen from alkyl sulphate, alkyl ether sulphate, alkyl sulphonate, alkyl aryl sulphonate, olefin sulphonate, acyl sarcosinate, acyl tauride, acyl isethionate, nonoalkyl s
  • anionic surfactants include: alkyl sulphates, such as sodium lauryl sulphate [eg. EMPICOL CX available from Albright & Wilson] , and triethanolamine lauryl sulphate [eg. EMPICOL TL40/T, available from Albright & Wilson] .
  • alkylether sulphates such as sodium lauryl ether sulphate
  • alkyl sulphonates such as sodium alkane (C 13 _ 18 ) sulphonate [eg. HOSTAPUR SAS 30, available from Hoechst] .
  • alkylaryl sulphonates such as sodium alkyl benzene sulphonate [eg. TEEPOL CM44, available from Shell] .
  • SUBSTITUTESHEET olefin sulphonates such as sodium olefin sulphonate (C 5 _ 18 ) [eg. HOSTAPUR OS, available from Hoechst] .
  • R 3 is chosen from C 6 . 1 alkyl
  • M is a counterion chosen from alkali metals, ammonium and substituted ammonium such as alkanolammonium.
  • acyl sarcosinate having the structure (51) is sodium lauryl sarcosinate [eg. HAMPOSYL L-95, available from Grace].
  • acyl taurides having the structure (52) :
  • R is chosen from C 8 . 18 alkyl
  • acyl tauride having the structure (52) is coconut methyl taurine [eg. FENOPEN TC 42, available from GAF] .
  • R 5 is chosen from C 8 _ 18 alkyl.
  • acyl isethionate having the structure (53) is sodium acyl isethionate [eg. JORDAPON Cl, available from Jordon] .
  • R 6 is chosen from C 10 _ 20 alkyl.
  • Examples of monoalkyl sulphosuccinates having the structure (54) include:
  • sodium lauryl sulphosuccinate eg. EMPICOL SLL, available from Albright & Wilson
  • magnesium alkyl sulphosuccinate eg. ELFANOL 616 Mg, available from AKZO.
  • sodium lauryl ethoxysulphosuccmate eg. EMPICOL SDD, available from Albright & Wilson.
  • coconut monoethanolamide ethoxysulphosuccmate eg. EMPICOL SGG
  • disodium lauryl polyglvcolether sulphosuccinate eg. SURTAGENE S30, available from CHEM-Y] .
  • polyethylene ⁇ lvcol sulphosuccinate eg. REWOPOL SBFA 30, available from REWO] .
  • dialkyl sulphosuccinates having the structure (55) :
  • R 7 and R 8 are the same or different, and are chosen from C 6 _ 1 alkyl.
  • dialkyl sulphosuccinate having the structure (55) is sodium dilauryl sulphosuccinate [eg. EMCOL 4500, available from Witco] .
  • R 9 is chosen from C 6 . 16 alkyl
  • n is 1. or 2.
  • acyl lactylate having the structure (6) is decanoyl lactylate [eg. PATIONIC 122a, available from Patterson, CJ] .
  • ethyl carboxlates such as alkyl C 12 _ 14 0(EO) ⁇ OCH 2 C0 2 Na [eg. AKYPO RLM 38, available from Akzo].
  • monoalkyl phosphates such as monolauryl phosphate, and dialkyl phosphates. such as dioctyl phosphate.
  • the shampoo compositions of the invention also comprise amphoteric surfactant.
  • Suitable amphoteric surfactants are derivatives of aliphatic quaternary ammonium, phosphonium and sulphonium ⁇ ompunds, wherein the aliphatic radicals contain from 8 to 18 carbon atoms, and may be straight chain or branched, and further contain an anionic water-solubilising group, such as carboxyl, sulphonate, sulphate, phosphate or phosphonate.
  • Preferred amphoteric surfactants include:
  • Alkyl betaines having the structure (57) :
  • R 10 is C ⁇ alkyl
  • alkyl betaine having the structure (57) is lauryldimethyl betaine [eg. EMPIGEN BB, available from Albright & Wilson] .
  • Alkylamidopropyl betines having the structure (58) :
  • alkylamidopropyl betaine having the structure (58) is cocamidcpropyl betaine [eg. TEGOBETAIN L7, available from Goldsch idt) .
  • Alkylamphoqlvcinates or Alkylamphopropionates having the structure (59) :
  • R 11 is chosen from H, CH 2 COO " and (CH 2 ) 2 COO "
  • R 12 is chosen from CH 2 COO " and (CH 2 ) 2 COO ⁇
  • Suitable examples of compounds (59) are cocoamphoglycinate (available from GAF) , and cocoamphopropionate.
  • R 13 is chosen from C 12 _ 16 alkyl alkylamido groups.
  • An example of a sultaine having the structure (60) is cocamidopropylhydroxysultaine [eg. CYCLOTERIC BET-CS, available from Alcolac) .
  • amphoteric surfactant are lauryl dimethyl betaine and cocamidopropyl betaine.
  • amphoteric surfactants can contribute to the foaming of the shampoo of the invention, while ameliorating the harshness of the anionic surfactant.
  • the shampoo composition of the invention can also comprise alkoxylated or glycosidic nonionic surfactant having an HLB of 8 or more. Above this value nonionics generally form clear isotropic solutions in combination with the other surfactants in the ranges defined above.
  • Preferred nonionic surfactants are polyoxyethylene alkyl esters and polyoxyethylene alkyl ethers and alkyl p ⁇ lyglycosides.
  • a suitable example of a polyoxyethylene alkyl ester is that having the CTFA designation Polysorbate 80 which is a mixture of oleate esters of sorbitol and sorbitol anhydrides, condensed with approximately 20 moles of ethylene oxide. Also suitable is Polysorbate 20 which is a mixture of laurate esters or sorbitol and sorbitol anhydrides condensed with approximately 20 moles of ethylene oxide.
  • Polysorbate 80 and Polysorbate 20 are available commercially as TWEEN 80 and TWEEN 20 respectively, from ICI Americas.
  • compositions of the invention are also suitable for use in the compositions of the invention.
  • polyethylene glycol ether of Cg.- ⁇ alcohol with an average of 8 ethoxy units which is available commercially as NONIDET LE-8T or as SYNPERONIC 91-8T
  • polyethylene glycol ether of C 12 _ 13 alcohol with an average of 9 ethoxy units which is available commercially as DOBANOL 25-9.
  • alkyl polyglycosides include the glycosides of glucose or glucose oligomers where the alkyl chain can be C 8 . 16 and the average number of glucose units is 1 to 2.
  • a suitable example is ORAMIX NS 10 which is the glucoside of C 10 . 12 fatty alcohol with an average of about 1.5 glucose units.
  • the amount of surfactant that can be present in the composition accordingly to the invention is up to 30%, preferably from l to 20% by weight of the composition.
  • adjuncts examples include antioxidants, such butyl hydroxy toluene; sunscreens, such as octyl methoxycinnamate and butylmethoxy di-benzoyl methane; film forming agents, such as perfluoropolymethylisopropyl ether humectants, such as glycerol, sorbitol, 2-pyrrolidone-5-carboxylate, dibutylphthalate, gelatin, polyethylene glycol, such as PEG 200-600; buffers, such as lactic acid together with a base such as triethanolamine or sodium hydroxide; waxes, such as beeswax, ozokerite wax, paraffin wax: plant extracts, such as Aloe vera, cornflower, witch hazel, elderflower, cucumber; thickeners; activity enhancers; colourants; and perfumes. Cosmetic adjuncts can form the balance of the composition.
  • Cosmetic adjuncts can form the balance of the composition.
  • composition according to the invention is preferably preserved in such a manner that it will enjoy an extended shelf life following manufacture and prior to sale and use. Ideally the composition will have an indefinite shelf life.
  • the urea cycle intermediate is likely to be prone to attack by bacteria, moulds and fungi and other microbial influences, particularly at pH values near that of the skin that characterise the preferred composition.
  • the shelf-life of the composition can therefore be unacceptably short due to the biodegradation of the precursor unless steps are taken to preserve the composition.
  • the composition should preferably be free, or substantially free, from viable microbial contaminants that are capable of resulting in microbial spoilage of the composition, and/or biodegradation of the precursor prior to topical application of the composition to mammalian skin or hair. It is to be understood, however, that the invention is also concerned with compositions, as herein defined, which may contain viable but dormant microorganisms, such as bacterial spores, provided that the conditions of preservation do not result in substantial proliferation of the microorganisms prior to use of the composition.
  • composition according to the invention can be preserved by sterilisation to remove or kill substantially all viable microbial contaminants. This can be achieved for example by irradiation using a lethal dose of gamma rays, by heat sterilisation or by ultrafiltration using techniques that are well established in the pharmaceutical industry.
  • composition according to the invention can also be preserved by including in it a chemical preservative which functions to prevent the growth of or kill bacteria, fungi or other microorganisms.
  • Examples of chemical preservatives include ethanol, benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, sodium propionate and the methyl, ethyl, propyl and butyl esters of p-hydroxybenzoic acid.
  • the amount of chemical preservative that can be incorporated in the composition according to the invention will generally be from 0.05 to 5%, preferably from 0.1 to 2% by weight, the amount chosen being sufficient to arrest microbial proliferation.
  • composition according to the invention can also be preserved by the inclusion of a water activity depressant such as glycerol, propylene glycol, sorbitol, sugars and salts, for examples alkali metal halides sulphates and carboxylates.
  • a water activity depressant such as glycerol, propylene glycol, sorbitol, sugars and salts, for examples alkali metal halides sulphates and carboxylates.
  • a water activity depressant sufficient should be incorporated in the composition according to the invention to reduce the water activity (c_ w ) from 1 to ⁇ 0.9, preferably to ⁇ 0.85 and most preferably ⁇ 0.8, the lowest of these values being that at which yeasts, moulds and fungi will not proliferate.
  • the topical skin and/or hair treatment composition of the invention can be formulated shampoo or hair conditioner, or as a liquid or gel, or as a lotion having a viscosity of from 4,000 to 10,000 mPas, a fluid cream having a viscosity of from 10,000 to 20,000 mPas or a cream having a viscosity of from 20,000 to 100,000 mPas, or above.
  • the composition can be packaged in a container to suit its viscosity and intended use by the consumer.
  • a shampoo, conditioner, liquid, gel, lotion or fluid cream can be packaged in a bottle or a sachet or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation.
  • the composition can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar.
  • the invention accordingly also provides a closed container containing a cosmetically acceptable composition as herein defined.
  • the invention also provides a process for preparing a hair growth composition which comprises the steps of mixing an effective amount of a urea cycle intermediate, as herein defined, together with a cosmetically acceptable carrier for the intermediate.
  • a process for preparing a hair growth composition which comprises the steps of mixing an effective amount of a urea cycle intermediate, as herein defined, together with a cosmetically acceptable carrier for the intermediate.
  • the invention accordingly also provides for the use of a urea cycle intermediate, as herein defined, for topical application to mammalian skin or hair for increasing or maintaining hair growth.
  • compositions according to the invention are primarily intended for topical application to the scalp of the human subject, particularly where the head is already bald or balding, in order to convert vellus hair to growth as terminal hair, or to increase the rate of growth of terminal hair.
  • the compositions can also be applied prophylactically to the hair and hence the scalp to reduce or prevent the onset of baldness, by maintaining the hair in a healthy, growing state, with less that usual hair loss.
  • the amount of the composition and the frequency of application to the hair and/or scalp can vary widely, depending on personal needs, but it is suggested as an example that topical application of from 0.1 to 5g daily containing from 0.00001 to lg of a selected urea cycle intermediate over the period of at least six months will in most cases result in an improvement in hair growth.
  • This test includes the important step of isolating hair follicles having an undamaged hair bulb from human skin, for example, facelift skin, by microdissection.
  • the method employed is described by Philpott et al; in J Cell
  • the critical step of separating the hair follicle with intact undamaged hair bulb from the subcutaneous fatty tissue in which it is situated accordingly involves severing the hair shaft of the follicle at a point below the epidermis of skin surface, so as to leave the hair bulb intact and undamaged while still bearing a portion of the hair shaft.
  • the hair shaft of the follicle is severed at the dermal-subcutaneous fat interface.
  • Any suitable cutting instrument can be employed to sever the hair shaft in this manner, but a keratotome or a scalpel are preferred.
  • the hair bulb with a hair shaft stump attached is then isolated from the skin by mechanically separating the hair from loosely adhering subcutaneous fat which normally surrounds the hair bulb. This is achieved after the dermis or upper layer of the skin has been separated and removed, to avoid damaging the hair bulb as it is pulled away.
  • the hair bulb together with hair shaft stump attached is then transferred in an otherwise undamaged and fully functioning, viable state to a nutrient medium.
  • the hair follicles isolated by the technique described herein are transferred to a suitable culture' medium for subsequent testing of substances that can then influence their future development.
  • isolated hair follicles obtained from facelift skin are maintained in 1 ml of Williams E medium, supplemented with L-glutamine (2mM) , insulin (10 ⁇ g/ml) , hydrocortisone (lOng/ml) and antibiotics, either with or without a test hair growth substance (urea cycle intermediate) .
  • the medium was incubated at 37°C in an atmosphere of 5% C0 2 + 95% air in individual wells of a 24 multiwell dish (Corning) , which permits detailed measurements to be made of the length of individual hair follicles.
  • Williams E medium is available from FLOW Laboratory under Catalogue No. 12-502. The formula of Williams E medium is described by Williams GM, et al., in Experimental Cell Research &9 (1971) on page 106.
  • the response of an isolated hair follicle to a test substance can accordingly be assessed by measuring the increase in length, if any, in the presence of a test substance against a control.
  • the in vitro method described herein was used to assess the effect of three urea cycle intermediate, namely arginine hydrochloride, ornithine hydrochloride and citrulline, when used in the presence of- glutamine, compared with glutamine alone, to demonstrate the superiority of the urea cycle intermediates over glutamine alone.
  • a test procedure for total protein synthesis utilised a similar culture of isolated follicles.
  • the follicles were cultured in arginine-deficient Williams E medium supplemented so as to contain 0.287mM, 0.574mM or 1.435mM arginine, for two days. Incubation was then continued for a further three hours in the presence of 14 C labelled leucine as well as the same concentration of arginine as before.
  • the follicles were removed from the radioactive media, and washed with 3 x 1ml of PBS supplemented with lOmM unlabelled leucine, to displace non-covalently bound 1 C-leucine. They were then homogenised in 1ml of ice-cold 0.1M K 2 EDTA, pH 12.3, in a hand-held glass/glass homogeniser. The homogenate was left at 4°C for 30 min. to release and dissolve the protein. Cell debris was removed by centrifugation, and HO ⁇ l samples of the supernatant removed for total protein determination by the Bio-Rad assay [based on Bradford, Anal.Biochem. , 72, 248 (1976)] .
  • the invention is illustrated by the following examples, each of which provides a composition comprising one or more specific metabolic intermediates of the urea cycle or derivatives thereof in in accordance with the invention. Selected metabolic intermediates are indicated by the s gagture numbers l is ted earlier in this specif ication .
  • This Example illustrates a lotion according to the invention which is suitable for topical application to the skin in order to enhance hair growth.
  • the lotion has the following formulation:
  • This Example illustrates a hair tonic which is suitable for application to hair or scalp.
  • the hair tonic has the following formulation:
  • This Example also illustrates a lotion which is suitable for topical application to the scalp.
  • the lotion has the following formulation:
  • This Example also illustrates a hair tonic which is suitable for application to hair or scalp.
  • the hair tonic has the following formulation:
  • the following formulations represent lotions which can be used topically in the treatment of bald or balding male or female heads.
  • the following formulations represent creams which can b used in the treatment of baldness.
  • This Example illustrates a water-in-oil high internal phas emulsion containing an amine according to the invention.
  • the emulsion consisted of 10% by volume oily phase and 90 by weight aqueous phase.
  • the oily phase and the aqueous phase had the followin constitution: % w/w
  • the emulsion was prepared by taking 10 parts by volume of the oily phase and to it adding slowly with stirring 90 parts by volume of the aqueous phase.
  • the high internal phase water-in-oil emulsion so formed can be applied topically to the scalp, to improve hair growth and regrowth.
  • examples 14 and 15 illustrate shampoos for use in washing the hair and scalp, and for promoting hair growth on the scalp.
  • This Example also illustrates a lotion which is suitable fo topical application to the scalp.
  • the lotion has the following formulation:
  • This example illustrates a powder composition according t the invention which can be applied topically to the scalp.
  • the following example illustrates a lotion according to th invention which can be applied topically to the scalp to preven hair loss and stimulate hair regrowth.
  • the hair tonics had the following formulation:
  • This example illustrates a shampoo which is suitable for topical application to hair in order to cleanse it, at the same time delivering a metabolic intermediate to the scalp to enhance hair growth or regrowth.
  • the shampoo had the following formulation:
  • This example illustrates a shampoo in accordance with the invention.
  • the shampoo had the following formulation:
  • This example illustrates a shampoo in accordance with this invention.
  • the shampoo had the following formulation:
  • This example illustrates a shampoo in accordance with this invention.
  • the shampoo had the following formulation:
  • Example 25 illustrate shampoos for use in washing the hair and scalp, and for promoting hair growth on the scalp.
  • Example 25 illustrate shampoos for use in washing the hair and scalp, and for promoting hair growth on the scalp.
  • Lauryl dimethylamino acetic acid betaine [30% AD] Coconut fatty acid diethanolamine Oleyl triethoxy phosphate (BRIPHOS 03D) Polyglycol-polyamine condensation resin (POLYQUART H) [50% active] Preservative, colouring matter, salt Intermediate (33) Perfume Water
  • This Example also illustrates a lotion which is suitable for topical application to the scalp.
  • the lotion has the following formulation: w/w
  • This example illustrates a powder composition according t the invention which can be applied topically to the scalp.
  • the following example illustrates a lotion according to th invention which can be applied topically to the scalp to preven hair loss and stimulate hair regrowth.
  • This example illustrates a shampoo which is suitable for topical application to hair in order to cleanse it, at the same time delivering a metabolic intermediate to the scalp to enhance hair growth or regrowth.
  • the shampoo had the following formulation:
  • This example illustrates a shampoo in accordance with th invention.
  • a pre-emulsion of polyisobutylene was made by mixing at room temperature the following ingredients in a Winkworth twin-Z-blade mixer (model MZ150) .
  • the pre-emulsion was then mixed, with stirring, with the additional ingredients of . the shampoo. to give a final composition as follows:
  • the shampoo is prepared using a simple hot process whereby all the ingredients except perfume are mixed at 70°C using a paddle stirrer. The mixture is then cooled slowly, and perfume added below 40°C.
  • Silicone emulsion comprises 50% by weight silicone oil (60,000 cs) , 4% by weight cetostearyl alcohol and 25% by weight SLES 2E0.
  • ammonium lauryl sulphate/ammonium lauryl ether sulphate and the BHT were heated in the main vessel to 75°C to melt the BHT, with constant stirring.
  • CARBOPOL 1342 was dispersed with stirring in 50% of the water, and the resulting dispersion added to the main vessel.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

A cosmetic composition for topical application to mammalian skin or hair, especially to a bald or balding human scalp, contains a metabolic intermediate from the urea cycle, or a derivative of such an intermediate, as an active agent serving to promote growth of hair.

Description

COSMETIC COMPOSITION
FIELD OF THE INVENTION
The invention relates to a cosmetic composition for topical application to mammalian skin or hair for increasing or at least maintaining hair growth, especially terminal hair growth on the human scalp.
BACKGROUND TO THE INVENTION
In recent years, there has been great emphasis on the promotion, enhancement, or at least maintenance of normal hair growth on the human head, particularly with men whose hair has started to recede, as in male pattern baldness, or with both men and women, as hair becomes thinner with advancing age. To this end, the market in "hair restorers" or "baldness cures" is growing.
It is well established that in most mammals, including man, hair does not grow continuously, but undergoes a cycle of activity involving alternate periods of growth and rest.
The hair growth cycle can be divided into three main stages, namely: i) an active stage known as anagen, during which the hair follicle penetrates deep into the dermis with the cells of the bulb dividing rapidly and differentiating to form the hair,
ii) a regressive stage known as catagen, which is heralded by the cessation of mitosis, and during which the follicle regresses upwards through the dermis and hair growth ceases, and
iii) a resting stage known as telogen, in which the regressed follicle contains a small secondary germ with an underlying ball of tightly packed dermal papilla cells.
The metabolism of the hair follicle during growth is not well understood. It has been established on microdissected hair follicles that glucose is a major fuel which the hair follicle requires for normal growth and that glucose is not oxidised to any great extent, as most of it is converted to lactate. [See, for example, Adachi K, Uno H. Glucose Metabolism of Growing and Resting Hair Follicles. Am J Physiol (1968) 215, 1234-1239; and Philpott M P, Kealey T, Metabolic Studies on Isolated Hair Follicles. J Invest Derm (1991) 9_β , 875-879].
In more recent work, we have shown that surprisingly, the hair follicle metabolises very little lipid fuels. Instead, glutamine has emerged as a major fuel which yields as much energy to the hair follicle as does glucose. This work is described in EP 490 581 (Unilever) where we have shown that glutamine stimulates the linear rate of hair growth to a significant extent. This suggests that glutaminolysis is a very important metabolic process for hair growth. As a result of further studies of glutaminolysis, we have now discovered that two thirds of the amine moiety derived from the conversion of glutamine to glutamate cannot be accounted for as ammonia. We therefore investigated its possible fate by examining other metabolic processes in human hair follicles, one of which, we hypothesised, is that the excess amine moieties were being disposed of by a functional urea cycle or part thereof, operating in the follicle.
The importance of the urea cycle for hair growth appears to reside in its ability to produce intermediates important for energy production in the follicle, which in turn enhance the efficiency of glutaminolysis. This is illustrated in Figure 1.
From this linked cycle, it can been seen that specific intermediates play an important part in promoting glutaminolysis. Thus, citrulline, which condenses with aspartate to form argininosuccinate, may also regulate the steps of arginine/urea synthesis by its availability, which would depend on oxaloacetate and in turn TCA cycle intermediates.
The availability of arginine may also be important for
RNA and protein biosynthesis due to its being an essential amino acid. The significance of ornithine may be due to its role in the generation of arginine in the follicle rather than to urea. In the process, fumarate is produced which can feed into the TCA cycle and contribute to anaplerotic reactions. ithout ornithine and arginine, the ammonia which results from a surplus of nitrogen caused by glutaminolysis may rise to toxic levels and prove fatal to cell function due its inhibition of transaminase reactions and hyperglutaminaemia. We have now put this hypothesis to the test and discovered that supplementing a composition intended for topical application with metabolic intermediates of the urea cycle can cause an increase in hair growth in excess of that previously observed for glutamine.
The invention is accordingly concerned with the use of these intermediates in hair follicle metabolism, so as to increase or maintain hair growth.
DEFINITION OF THE INVENTION
Broadly, the invention provides a composition which is suitable for topical application to mammalian skin or hair for increasing, enhancing or maintaining hair growth, which composition comprises: i) an effective amount of a metabolic intermediate of the urea cycle chosen from arginine, ornithine, citrulline, argininosuccinate, their salts, hydrosalts and precursors thereof, and mixtures thereof; and ii) a cosmetically acceptable vehicle for the intermediate.
In another aspect the invention provides a method of increasing, enhancing or maintaining hair growth by use of such a composition. Use is by topical application especially to the bald or balding human scalp.
DISCLOSURE OF THE INVENTION
The Urea Cycle Intermediate
The invention is concerned with the utilisation of a metabolic intermediate which is part of the urea cycle, or a derivative of such a metabolic intermediate, and its topical application for the purposes of increasing or maintaining hair growth, particularly on the human scalp. The urea cycle and its involvement in glutaminolysis (so important in hair growth) via the tricarboxylic acid
SUBSTITUTE SHEET (TCA) cycle is shown in Figure 1. From this, four metabolic intermediates of the urea cycle, namely arginine, ornithine, citrulline and argininosuccinate have been selected as possessing the ability to promote linear hair growth to an extent which is significantly greater than glutamine itself.
Each of these four metabolic intermediates can therefore incorporated into a composition for topical application to skin or hair, in particular the scalp, for promoting or at least maintaining hair growth.
It is also possible and indeed is generally more convenient to employ simple derivatives such as salts and hydro salts, as appropriate, of .these metabolic Intermediates. A particularly preferred example of a salt is the sodium salt, and a preferred example of a hydro salt is a hydrohalide especially the hyrochloride derivatives of these intermediates.
It is further possible to employ other derivatives including acyl, ester and peptide derivatives of these metabolic intermediates. These too may be used as salts or hydrosalts.
More particularly, derivatives as shown below in structures (1) to (4) can be employed.
Derivatives of arginine having the structure (1) :
NHR1
C=NH2 +
NH
(1)
(CH2):
H—C—NH,+
COOR2
Derivatives of ornithine having the structure (2) :
NH3 +
I (CH2)3 I (2)
H—C—NH3 +
I COOR2
Derivatives of citrulline having the structure (3) :
NHR1
C=0
NH
(3)
(CH2);
H—C—NH,+
COOR2 Derivatives of argininosuccinate having the structure (4):
COOR2 I
NHR1 CH2
I (CH2)3
I
H—C—NH3 +
COOR2
where R1 is chosen from:
(i) H-,
(ii) o-
-P=0
(iii) C-Α.- ,
(iv) a ino acid residues, or substituted amino acid residues where any free -NH2 group is modified to form a -NHCOC-Jiy or a -NHC-jHy group, and/or any free -COOH group is substituted to form a COOR2 group, and
(v) peptide residues comprising from 2 to 8 amino acid residues or substituted amino acid residues, which are substituted as defined in (iv) above;
the amino acid residues or substituted amino acid residues, as herein defined, being derived from one or more of the following amino acids:
L-α-alanine
L-β-alanine L-arginine
L-γ-amino butyric acid
L-asparagine
L-aspartic acid
L-citrulline L-cysteine
L-cystine
L-3,4-dihydroxyphenylalanine (DOPA)
L-glutamine
L-glutamic acid L-glycine
L-histidine
L-homoserine
L-hydroxylysine
L-hydroxyproline L-isoleucine
L-leucine
L-lysine
L-methionine
L-ornithine L-phenylalanine
L-proline
L-serine
L-threonine
L- ,N,N-trimethy1 glycine (betaine) L-tryptophan
L-tyrosine, and
L-valine; and where each R2 is chosen from:
(i) H+,
(ii) alkali metal cations chosen from Na+ and K+, (iϋ) NH4 + or alkanolam onium ions, and
(iv) C-Jiy-;
where x is a integer of from 1 to 22, and y is an integer of from 3 to 45;
and where each =NH2 + and -NH3 + group is associated with an hydrohalide, where the halide is preferably Cl" or. Br".
Preferred examples of hydrohalide derivatives of urea cycle intermediates are:
arginine hydrochloride (10) ornithine hydrochloride (11)
Preferred examples of alkali metal salt derivatives of urea cycle intermediates are:
sodium arginate (12) arginine phosphate, sodium salt (13) sodium arginosuccinate (14) potassium arginosuccinate (15)
Preferred examples of dipeptide derivatives of urea cycle intermediates are:
L-α-alanylarginine hydrochloride (15)
L-cystinylornithine (16)
L-methionylcitrulline (17)
L-arginylarginine (18) -ornithylcitrulline (19)
L-glutaminylarginine (20)
L-glutaminylcitrulline (21) L-tyrosinylarginine (22)
L-arginylmethionine (23)
L-ornithylmethionine (24)
L-citrullylmethionine (25) L-arginylaspartate (26)
L-arginylglutamate (27)
L-arginylleucine acetate salt (28)
L-arginyllysine acetate salt (29)
L-arginylphenylalanine acetate salt (30) L-ornithylaspartate (31)
and their corresponding hydrchalides or salts, where appropriate.
Preferred examples of other derivatives of urea cycle intermediates are:
methylarginine dihydrochloride (32) arginine ethyl ester dihydrochloride (33) ethylcitrulline (34) n-propylornithine (35) n-octylarginine (36) n-octylcitrulline (37) n-octylornithine (38)
The composition can comprise two or more urea cycle intermediates or derivatives thereof, as herein defined.
When the chosen urea cycle intermediate is citrulline, or a derivative thereof, it is preferably to include aspartate in the composition according to the invention, in view of the combination of citrulline and aspartate to from arginosuccinate, as is evident from Figure 1.
Likewise, when the chosen urea cycle intermediate is ornithine, or a derivative thereof, it is advantageous to include carbamoyl phosphate in the composition accordingly to the invention, as carbamoyl phosphate promotes the formulation of citrulline from ornithine, as can also be seen from Figure 1.
The total amount of the urea cycle intermediate or derivative thereof present in the composition according to the invention is an amount which is sufficient to induce maintain or increase hair growth. This amount will depend on the effectiveness of the intermediate, some being more effective than others, but in general an amount of from 0.001 to 99%, usually from 0.01 to 30% by weight of the composition will provide an adequate concentration for application to the skin, particularly the scalp, which can then be repeated as necessary to promote hair growth.
The Cosmeticallv Acceptable Vehicle
The composition according to the invention also comprises a solid, semi-solid or liquid cosmetically and/or physiologically acceptable vehicle, to enable the urea cycle intermediate, or derivative thereof, to be conveyed to the skin at an appropriate dilution. The nature of the vehicle will depend upon the method chosen for topical administration of the composition. The vehicle can itself be inert or it can possess physiological or pharmaceutical benefits of its own.
The selection of a vehicle for this purpose presents a wide range of possibilities depending on the required product form of the composition. Suitable vehicles can be classified as described hereinafter.
It should be explained that vehicles are substances which can act as diluents, dispersants, or solvents for the urea cycle intermediate, or derivative thereof, which therefore ensure that they can be applied to and distributed evenly over the hair and/or scalp at an appropriate concentration. The vehicle is preferably one which can aid penetration of the esters into the skin to reach the immediate environment of the hair follicle, compositions according to the invention can include water as a vehicle, and/or at least one cosmetically acceptable vehicle other than water.
Vehicles other than water can include liquid or solid emollients, solvents, humectants, thickeners and powders. Examples of each of these types of vehicle, which can be used singly or as mixtures of one or more vehicles, are as follows:
Emollients, such as stearyl alcohol, glyceryl monoricinoleate, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, eicosanyl alcohol, behenyl alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, cocoa butter, corn oil, cotton seed oil, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, evening primrose oil, soybean oil, sunflower seed oil, avocado oil, sesame seed oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, petroleum jelly, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, myristyl myristate;
Propellants, such as propane, butane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide;
Solvents, such as ethyl alcohol., methylene chloride, isopropanol, acetone, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxidε, dimethyl formamide, tetrahydrofuran;
Powders, such as chalk, talc, fullers earth, kaolin, starch, gums, colloidal silica sodium polyacrylate, tetra alkyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate, ethylene glycol distearate;
The cosmetically acceptable vehicle will usually form from 10 to 99.999%, preferably from 10 to 99% and most preferably from 50 to 99% by weight of the emulsion, and can, in the absence of other cosmetic adjuncts, form the balance of the composition.
Activity Enhancer
The composition according to the invention can also optionally comprise an activity enhancer.
The activity enhancer can be chosen from a wide variety of molecules which can function in different ways to enhance the hair growth effects of the urea cycle intermediate. Particular classes of activity enhancers include (a) other hair growth stimulants, (b) penetration enhancers and (c) cationic polymers, whose presence can further improve the delivery of the ester through the stratum corneum to its site of action in the immediate environment of the hair follicle.
Some activity enhancers can also function as vehicles for the ester. .a. Other Hair Growth Stimulants
i. Examples of other substances which themselves possess the ability to stimulate or increase hair growth include, for example:
Benzalkonium chloride
Benzethonium chloride
Phenol Estradiol
Diphenhydramine hydrochloride
Chlorpheniramine maleate
Chlorophyllin derivatives
Cholesterol Salicylic acid
Cystine
Methionine
Red pepper tincture
Benzyl nicotinate dl-Menthol
Peppermint oil
Calcium pantothenate
Panthenol
Castor oil Hinokitiol
Prednisolone
Resorcinol
Further substances which themselves possess the ability to increase the rate of terminal hair growth include:
ii(a) α-1,4 Esterified disaccharides described by Choay S.A. in EP-A 0 064 012; and
ii(b) Esterified oligosaccharides as described by Unilever in EP-A 0 211 610. iii. Minoxidil glucuronides, as described by Unilever in EP 0 242 967.
iv. Minoxidil sulphates, as described by The Upjohn Co. in WO 86/04231.
v. Minoxidil, and other derivatives thereof as described by The Upjohn Co. in US 4 139 619.
vi. Ethylenediaminetetraacetic acid or salts thereof, as described by Redken Laboratories, Inc. in US 4 814 351.
vii. Direct proteoglycanase inhibitors, such as 1,10- phenanthroline, as described by Unilever in EP 0 277 428.
viii. Glycosaminoglycanase inhibitors, as described by Unilever in EP 0 277 428, such as D-Glucaro-1,4- lactone.
ix. Glycosaminoglycanase inhibitors, as described by Unilever in EP 0 277 428, such as N- acetylglucosamine.
x. Glycosa inoglycan chain cellular uptake inhibitors, as described by Unilever in EP 0 277 428, such as hexuronic acid and esters thereof.
xi. Chemical inhibitors of glycosidase activity, as described by Unilever in EP 0 334 586, chosen from lactams, such as D-glucaro-l,5-lactam.
xii. Chemical activators of protein kinase C enzymes, as described by Unilever in EP 0 334 585 chosen from diacylglycerols, such as 1,2-Dioleoyl-sn- glycerol.
Xlll. Glycosaminoglycanase inhibitors, as described by Unilever in EP 0 348 184, such as 6-methyl- glucaro-1,4-lactone.
xiv. Glycosaminoglycanase inhibitors, as described by Unilever in EP 0 348 184, chosen from acylated monosaccharides , such as 2-propionamido-2- deoxyglucose.
xv. Esters of pyroglutamic acid, as described by Lever Brothers Company in US 4 774 255, such as pyroglutamic acid ,n-hexyl ester and pyroglutamic acid n-octyl ester.
xvi. Hexosaccharic acids or an acylated hexosacchariσ acids, or salts or esters thereof, as described by Unilever in EP 378 388, such as glucosaccharic acid, and its disodium salt.
xvii. Aryl-substituted ethylenes as described by Unilever in EP 403 238, such as 1, l-dicarboxy-2- (4-hydroxyphenyl)ethylene.
(b) Penetration Enhancers
As has been stated earlier, the presence of a penetration enhancer can potentiate the benefit of the urea cycle intermediate or derivative thereof by improving its delivery through the stratum corneum to its site of action in the hair follicle.
The penetration enhancer can accordingly function in a variety of ways. It can for example, improve the distribution of the urea cycle intermediate on the skin surface or, it can increase its partition into the skin from the composition when applied topically, so aiding its passage to its site of action. Other mechanisms enhancing the benefit of the hair growth promoter may also be involved.
Examples of penetration enhancers include:
2-methyl propan-2-ol Propan-2-ol
Ethyl-2-hydroxypropanoate
Hexan-2,5-diol
POE(2) ethyl ether
Di(2-hydroxypropy1) ether Pentan-2,4-diol
Acetone
POE(2) methyl ether
2-hydroxypropionic acid
2-hydroxyoctanoic acid Propan-1-ol
1,4 Dioxane
Tetrahydrofuran
Butan-l,4-diol
Propylene glycol dipelargonate Polyoxypropylene 15 stearyl ether
Octyl alcohol
POE ester of oleyl alcohol
Oleyl alcohol
Lauryl alcohol Dioctyl adipate
Dicapryl adipate
Diisopropyl adipate
Diisopropyl sebacate
Dibutyl sebacate Diethyl sebacate
Dimethyl sebacate
Dioctyl sebacate Dibutyl suberate
Dioctyl azelate
Debenzyl sebacate
Dibutyl phthalate Dibutyl azelate
Ethyl myristate
Dimethyl azelate
Butyl myristate
Dibutyl succinate Dideσyl phthalate
Decyl oleate
Ethyl caproate
Ethyl salicylate
Isopropyl palmitate Ethyl laurate
2-ethyl-hexyl pelargonate
Isopropyl isostearate
Butyl laurate
Benzyl benzoate Butyl benzoate
Hexyl laurate
Ethyl caprate
Ethyl caprylate
Butyl stearate Benzyl salicylate
2-hydroxypropanoic acid
2-hyroxyoctanoic acid.
Dimethyl sulphoxide
N,N-Dimethy3 acetamide N,N-Dimethyl formamide
2-Pyrrolidone l-Methyl-2-pyrrolidone
5-Methy1-2-pyrro1idone
1,5-Dimethyl-2-pyrrolidone l-Ethyl-2-pyrrolidone
Phosphine oxides
Sugar esters Tetrahydrofurfural alcohol Urea
Diethyl-m-toluamide, and l-Dodecylazacyloheptan-2-one
(c) Cationic Polymers
As stated earlier, the presence of a cationic polymer can potentiate the benefit of the urea cycle intermediate or derivative thereof by improving its delivery to the hair and scalp. Examples of preferred cationic polymers include:
Guar Hydroxypropyltrimonium chloride Quaternium-19
Quaternium-23
Quaternium-40
Quaternium-57
Poly(dipropyldiallylammonium chloride) Poly(methyl-γ-propaniodiallylammonium chloride)
Poly(diallylpiperidinium chloride)
Poly(vinyl pyridinium chloride)
Quaternised poly (vinyl alcohol)
Quaternised poly (dimethylaminoethylmethacrylate) ; and mixtures thereof
The amount of activity enhancer, when employed in accordance with the invention, will normally be from 0.1 to 50%, preferably from 0.5 to 25% and most preferably from 0.5 to 10% by weight of the composition.
OPTIONAL SKIN BENEFIT MATERIALS AND COSMETIC ADJUNCTS
A particularly convenient form of the composition according to the invention is an emulsion, in which case an oil or oily material will normally be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion, depending largely on the average hydrophilic-lyophilic balance (HLB) of the emulsifier employed.
Oil or oily material
The composition according to the invention can optionally comprise one or more oils or other materials having the properties of an oil.
Examples of suitable oils include mineral oil and vegetable oils, and oil materials, such as those already proposed herein as emollients. Other oils or oily materials include silicone oils, both volatile and non- volatile, such as polydimethyl siloxanes.
The oil or oily material, when present for . the purposes for forming an emulsion, will normally form up to 90%, preferably from 10 to 80% by volume of the composition.
Emulsifier
The composition according to the invention can also optionally comprise one or more emulsifiers the choice of which will normally determine whether a water-in-oil or and oil-in-water emulsion is formed.
When a water-in-oil emulsion is required, the chosen emulsifier or emulsifiers should normally have an average HLB value of from 1 to 6. When an oil-in-water emulsion is required, a chosen emulsifier or emulsifiers should have an average HLB value of >6.
Examples of suitable emulsifiers are set below in Table 1 in which the chemical name of the emulsifiers is given together with an example of a trade name as commercially available, and the average HLB value.
Table 1
Chemical Name Trade Name HLB Value of Emulsifier
Sorbitan trioleate Sorbitan tristearate Glycerol monooleate Glycerol monostearate Glycerol monolaurate Sorbitan sesquioleate Sorbitan monooleate Sorbitan monostearate Poloxyethylene (2) stearyl ether Poloxyethylene sorbitol beeswax derivative PEG 200 dilaurate Sorbitan monopalraitate Polyoxyethylene (3.5) nonyl phenol PEG 200 monostearate
Sorbitan monolaurate PEG 400 dioleate
Polyoxyethylene (5) monostearate Ethofat 60-16 9.0 Polyoxyethylene (4) sorbitan monostearate Tween 61 9.6 Polyoxyethylene (4) lauryl ether Brij 30 9.7 Polyoxyethylene (5) sorbitan monooleate PEG 300 monooleate Polyoxyethylene (20) sorbitan tristearate
Polyoxyethylene (20) sorbitan trioleate Polyoxyethylene (8) monostearate Myrj 45 11.1 PEG 400 monooleate Emerest 2646 11.7
PEG 400 monostearate Tegester PEG 400 11.9 Polyoxyethylene 10 monooleate Ethofat 0/20 12.2 Polyoxyethy1ene (10) stearyl ether Brij 76 12.4
Polyoxyethylene (10) cetyl ether Brij 56 12.9 Polyoxyethylene (9.3) octyl phenol Triton X-100 13.0 Polyoxyethylene (4) sorbitan monolaurate PEG 600 monooleate PEG 1000 dilaurate Polyoxyethylene sorbitol lanolin derivative
Polyoxyethylene (12) lauryl ether PEG 1500 dioleate Polyoxyethylene (14) laurate Arosurf HFL-714 14.8
Polyoxyethylene (20) sorbitan monostearate Tween 60 14.9 Polyoxyethylene 20 sorbitan monooleate Tween 80 15.0 Polyoxyethylene (20) stearate Myrj 49 15.0 Polyoxyethylene (20) stearyl ether Brij 78 15.3 Polyoxyethylene (20) sorbitan monopalmitate Tween 40 15.6 Polyoxyethylene (20) cetyl ether Brij 58 15.7 Polyoxyethylene (25) oxypropy1ene monostearate G-2162 16.0 Polyoxyethylene (20) sorbitol monolaurate Tween 20 16.7 Polyoxyethylene (23) lauryl ether Brij 35 16.9 Polyoxyethylene (50) monostearate Myrj 53 17.9 PEG 4000 monostearate Pegosperse 4000
MS 18.7
The foregoing list of emulsifiers is not intended to be limiting and merely exemplifies selected emulsifiers which are suitable for use in accordance with the invention.
It is to be understood that two or more emulsifiers can be employed if desired.
The amount of emulsifier or mixtures thereof, to be incorporated in the composition of the invention, when appropriate is from 1 to 50%, preferably from 2 to 20% and most preferably from 2 to 10% by weight of the composition.
Water
The composition of the invention can also comprise water, usually up to 90%, preferably from 5 to 80% by volume. Water can function as the cosmetically acceptable vehicle.
Silicone Surfactant
The composition of the invention can also optionally comprise a high molecular weight silicone surfactant which can also act as an emulsifier, in place of or in addition to the optional emulsifier(s) already mentioned.
The silicone surfactant is a high molecular weight polymer of dimethyl polysiloxane with polyoxyethylene and/or polyoxypropylene side chains having a molecular weight from 10,000 to 50,000.
The dimethyl polysiloxane polymer is conveniently provided as a dispersion in a volatile siloxane, the dispersion comprising, for example, from 1 to 20% by volume of the polymer and from 80 to 99% by volume of the volatile siloxane. Ideally, the dispersion consists of a 10% by volume of the polymer dispersed in the volatile siloxane.
Examples of the volatile siloxanes in which the polysiloxane polymer can be dispersed include polydimethyl siloxane (pentamer and/or hexamer) .
A particularly preferred silicone surfactant is cyclomethicone and dimethicone copolyol, such as DC 3225C
Formulation Aid available from DOW CORNING. Another is laurylmethicone copolyol, such as DC Q2-5200, also available from Dow Corning.
The amount of silicone surfactant, when present in the composition will normally be up to 25%, preferably from 0.5 to 15% by weight of the emulsion. Surfactants
The composition for use in the method according to the invention can be formulated as a shampoo and will then accordingly comprise one or more surfactants which are cosmetically acceptable and suitable for topical application to the hair. Examples of suitable shampoo surfactants are given below. When a composition is formulated to contain surfactant in a quantity of 4% by weight or more, it may prove desirable to use the metabolic intermediate in a concentration of more than 5% by weight, possibly more than 8% by weight. This may even prove desirable when surfactant is present in lower concentrations, such as 1% by weight or more.
Anionic Surfactant
The composition of the invention can comprise an anionic surfactant which is preferably chosen from alkyl sulphate, alkyl ether sulphate, alkyl sulphonate, alkyl aryl sulphonate, olefin sulphonate, acyl sarcosinate, acyl tauride, acyl isethionate, nonoalkyl sulphosuccinate, dialkylsulphosuccinate, acryl lactylate, acylated α-amino acid, alkyl carboxylate, monoalkyl phosphate and dialkyl phosphate.
Specific examples of anionic surfactants include: alkyl sulphates, such as sodium lauryl sulphate [eg. EMPICOL CX available from Albright & Wilson] , and triethanolamine lauryl sulphate [eg. EMPICOL TL40/T, available from Albright & Wilson] .
alkylether sulphates, such as sodium lauryl ether sulphate
[eg. EMPICOL ESB70, available from Albright & Wilson] .
alkyl sulphonates, such as sodium alkane (C13_18) sulphonate [eg. HOSTAPUR SAS 30, available from Hoechst] .
alkylaryl sulphonates, such as sodium alkyl benzene sulphonate [eg. TEEPOL CM44, available from Shell] .
SUBSTITUTESHEET olefin sulphonates. such as sodium olefin sulphonate (C5_18) [eg. HOSTAPUR OS, available from Hoechst] .
acyl sarcosinates. having the structure: (51)
R3 — C — N — CH2COOM (51)
I CH3
where R3 is chosen from C6.1 alkyl, and
M is a counterion chosen from alkali metals, ammonium and substituted ammonium such as alkanolammonium.
An example of an acyl sarcosinate having the structure (51) , is sodium lauryl sarcosinate [eg. HAMPOSYL L-95, available from Grace].
acyl taurides, having the structure (52) :
O
R C — N (CH2)2S03M (52)
CH,
where R is chosen from C8.18 alkyl
An example of an acyl tauride having the structure (52) is coconut methyl taurine [eg. FENOPEN TC 42, available from GAF] . acyl isethionates . having the structure ( 53 ) :
R5 — C _ O — (CH2) 2S03M (53 )
where R5 is chosen from C8_18 alkyl.
An example of an acyl isethionate having the structure (53) is sodium acyl isethionate [eg. JORDAPON Cl, available from Jordon] .
monoalkyl sulphosuccinates. having the structure (54)
R6 — O — C CH2CH COOM (54)
I S03M
where R6 is chosen from C10_20 alkyl.
Examples of monoalkyl sulphosuccinates having the structure (54) include:
sodium lauryl sulphosuccinate [eg. EMPICOL SLL, available from Albright & Wilson] .
magnesium alkyl sulphosuccinate [eg. ELFANOL 616 Mg, available from AKZO] .
sodium lauryl ethoxysulphosuccmate [eg. EMPICOL SDD, available from Albright & Wilson] .
coconut monoethanolamide ethoxysulphosuccmate [eg. EMPICOL SGG] . disodium lauryl polyglvcolether sulphosuccinate [eg. SURTAGENE S30, available from CHEM-Y] .
polyethyleneαlvcol sulphosuccinate [eg. REWOPOL SBFA 30, available from REWO] .
dialkyl sulphosuccinates. having the structure (55) :
R 70c — CH2CH — COOR8 ( 55)
S03M
where R7 and R8 are the same or different, and are chosen from C6_1 alkyl.
An example of a dialkyl sulphosuccinate having the structure (55) is sodium dilauryl sulphosuccinate [eg. EMCOL 4500, available from Witco] .
acyl lactylatesf having the structure (56) :
H
R9 — C — (O — C — C)n OM (56)
CH,
where R9 is chosen from C6.16 alkyl,
and n is 1. or 2.
An example of an acyl lactylate having the structure (6) is decanoyl lactylate [eg. PATIONIC 122a, available from Patterson, CJ] . acylated a-amino acids, such as sodium lauroyl glutamate [eg. ACYLGLUTAMATE LS-11, available from Ajinomoto Co. Ine] .
ethyl carboxlates. such as alkyl C12_140(EO)<OCH2C02Na [eg. AKYPO RLM 38, available from Akzo].
monoalkyl phosphates such as monolauryl phosphate, and dialkyl phosphates. such as dioctyl phosphate.
Amphoteric Surfactant
The shampoo compositions of the invention also comprise amphoteric surfactant. Suitable amphoteric surfactants are derivatives of aliphatic quaternary ammonium, phosphonium and sulphonium σompunds, wherein the aliphatic radicals contain from 8 to 18 carbon atoms, and may be straight chain or branched, and further contain an anionic water-solubilising group, such as carboxyl, sulphonate, sulphate, phosphate or phosphonate.
Preferred amphoteric surfactants include:
Alkyl betaines. having the structure (57) :
CH 3
R10 — N+ — CH2COO" (57)
I CH3
where R10 is C^^ alkyl.
An example, of an alkyl betaine having the structure (57) is lauryldimethyl betaine [eg. EMPIGEN BB, available from Albright & Wilson] . Alkylamidopropyl betines, having the structure (58) :
O CH3
1 I R10-C-N-(CH2) z-N'-CKzCOO' (58)
I CH3
An example of an alkylamidopropyl betaine having the structure (58) is cocamidcpropyl betaine [eg. TEGOBETAIN L7, available from Goldsch idt) .
Alkylamphoqlvcinates or Alkylamphopropionates having the structure (59) :
R10-C-N-(CH2)2-N+-(CH2)2OH (59)
where R11 is chosen from H, CH2COO" and (CH2)2COO", and R12 is chosen from CH2COO" and (CH2)2COO~
Suitable examples of compounds (59) are cocoamphoglycinate (available from GAF) , and cocoamphopropionate.
Sultaines, having the structure (60)
CH3 OH
R i3_N + CH2-CH-CH2-S03 " (60)
CH,
where R13 is chosen from C12_16 alkyl alkylamido groups. An example of a sultaine having the structure (60) is cocamidopropylhydroxysultaine [eg. CYCLOTERIC BET-CS, available from Alcolac) .
The most preferred amphoteric surfactant are lauryl dimethyl betaine and cocamidopropyl betaine.
Such amphoteric surfactants can contribute to the foaming of the shampoo of the invention, while ameliorating the harshness of the anionic surfactant.
Nonionic Surfactant
The shampoo composition of the invention can also comprise alkoxylated or glycosidic nonionic surfactant having an HLB of 8 or more. Above this value nonionics generally form clear isotropic solutions in combination with the other surfactants in the ranges defined above. Preferred nonionic surfactants are polyoxyethylene alkyl esters and polyoxyethylene alkyl ethers and alkyl pσlyglycosides.
A suitable example of a polyoxyethylene alkyl ester is that having the CTFA designation Polysorbate 80 which is a mixture of oleate esters of sorbitol and sorbitol anhydrides, condensed with approximately 20 moles of ethylene oxide. Also suitable is Polysorbate 20 which is a mixture of laurate esters or sorbitol and sorbitol anhydrides condensed with approximately 20 moles of ethylene oxide.
Polysorbate 80 and Polysorbate 20 are available commercially as TWEEN 80 and TWEEN 20 respectively, from ICI Americas.
Also suitable for use in the compositions of the invention is the polyethylene glycol ether of Cg.-^ alcohol with an average of 8 ethoxy units, which is available commercially as NONIDET LE-8T or as SYNPERONIC 91-8T, and the polyethylene glycol ether of C12_13 alcohol with an average of 9 ethoxy units which is available commercially as DOBANOL 25-9.
Particularly useful alkyl polyglycosides include the glycosides of glucose or glucose oligomers where the alkyl chain can be C8.16 and the average number of glucose units is 1 to 2. A suitable example is ORAMIX NS 10 which is the glucoside of C10.12 fatty alcohol with an average of about 1.5 glucose units.
The amount of surfactant that can be present in the composition accordingly to the invention is up to 30%, preferably from l to 20% by weight of the composition.
Other Cosmetic Adjuncts
Examples of conventional adjuncts which can optionally be employed include antioxidants, such butyl hydroxy toluene; sunscreens, such as octyl methoxycinnamate and butylmethoxy di-benzoyl methane; film forming agents, such as perfluoropolymethylisopropyl ether humectants, such as glycerol, sorbitol, 2-pyrrolidone-5-carboxylate, dibutylphthalate, gelatin, polyethylene glycol, such as PEG 200-600; buffers, such as lactic acid together with a base such as triethanolamine or sodium hydroxide; waxes, such as beeswax, ozokerite wax, paraffin wax: plant extracts, such as Aloe vera, cornflower, witch hazel, elderflower, cucumber; thickeners; activity enhancers; colourants; and perfumes. Cosmetic adjuncts can form the balance of the composition. Preservation of the Composition
The composition according to the invention is preferably preserved in such a manner that it will enjoy an extended shelf life following manufacture and prior to sale and use. Ideally the composition will have an indefinite shelf life.
It is accordingly apparent that the urea cycle intermediate is likely to be prone to attack by bacteria, moulds and fungi and other microbial influences, particularly at pH values near that of the skin that characterise the preferred composition. The shelf-life of the composition can therefore be unacceptably short due to the biodegradation of the precursor unless steps are taken to preserve the composition.
In order to be preserved, the composition should preferably be free, or substantially free, from viable microbial contaminants that are capable of resulting in microbial spoilage of the composition, and/or biodegradation of the precursor prior to topical application of the composition to mammalian skin or hair. It is to be understood, however, that the invention is also concerned with compositions, as herein defined, which may contain viable but dormant microorganisms, such as bacterial spores, provided that the conditions of preservation do not result in substantial proliferation of the microorganisms prior to use of the composition.
Examples of the methods that can be employed to achieve preservation of the composition, includes the following: .i. Sterilisation
The composition according to the invention can be preserved by sterilisation to remove or kill substantially all viable microbial contaminants. This can be achieved for example by irradiation using a lethal dose of gamma rays, by heat sterilisation or by ultrafiltration using techniques that are well established in the pharmaceutical industry.
■ii. Chemical Preservative
The composition according to the invention can also be preserved by including in it a chemical preservative which functions to prevent the growth of or kill bacteria, fungi or other microorganisms.
Examples of chemical preservatives include ethanol, benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, sodium propionate and the methyl, ethyl, propyl and butyl esters of p-hydroxybenzoic acid. The amount of chemical preservative that can be incorporated in the composition according to the invention will generally be from 0.05 to 5%, preferably from 0.1 to 2% by weight, the amount chosen being sufficient to arrest microbial proliferation.
(iii) Water activity depressants
The composition according to the invention can also be preserved by the inclusion of a water activity depressant such as glycerol, propylene glycol, sorbitol, sugars and salts, for examples alkali metal halides sulphates and carboxylates. When employing a water activity depressant, sufficient should be incorporated in the composition according to the invention to reduce the water activity (c_w) from 1 to < 0.9, preferably to < 0.85 and most preferably < 0.8, the lowest of these values being that at which yeasts, moulds and fungi will not proliferate.
PRODUCT FORM AND PACKAGING
The topical skin and/or hair treatment composition of the invention can be formulated shampoo or hair conditioner, or as a liquid or gel, or as a lotion having a viscosity of from 4,000 to 10,000 mPas, a fluid cream having a viscosity of from 10,000 to 20,000 mPas or a cream having a viscosity of from 20,000 to 100,000 mPas, or above.
The composition can be packaged in a container to suit its viscosity and intended use by the consumer. For example, a shampoo, conditioner, liquid, gel, lotion or fluid cream can be packaged in a bottle or a sachet or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation. When the composition is a cream, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar.
The invention accordingly also provides a closed container containing a cosmetically acceptable composition as herein defined.
Process
The invention also provides a process for preparing a hair growth composition which comprises the steps of mixing an effective amount of a urea cycle intermediate, as herein defined, together with a cosmetically acceptable carrier for the intermediate. Use of the urea cycle intermediate for increasing or maintaining hair growth
The invention accordingly also provides for the use of a urea cycle intermediate, as herein defined, for topical application to mammalian skin or hair for increasing or maintaining hair growth.
The compositions according to the invention are primarily intended for topical application to the scalp of the human subject, particularly where the head is already bald or balding, in order to convert vellus hair to growth as terminal hair, or to increase the rate of growth of terminal hair. The compositions can also be applied prophylactically to the hair and hence the scalp to reduce or prevent the onset of baldness, by maintaining the hair in a healthy, growing state, with less that usual hair loss.
The amount of the composition and the frequency of application to the hair and/or scalp can vary widely, depending on personal needs, but it is suggested as an example that topical application of from 0.1 to 5g daily containing from 0.00001 to lg of a selected urea cycle intermediate over the period of at least six months will in most cases result in an improvement in hair growth.
EVALUATION OF EFFICACY OF THE UREA CYCLE INTERMEDIATES USING THE IN VITRO HAIR FOLLICLE GROWTH TEST
The effect of compounds on hair growth was assessed using an in vitro test which measures the elongation of isolated human hair follicles in a culture medium. Isolation of the hair follicle from skin
This test includes the important step of isolating hair follicles having an undamaged hair bulb from human skin, for example, facelift skin, by microdissection. The method employed is described by Philpott et al; in J Cell
Sci 97, 463, (1990) .
The critical step of separating the hair follicle with intact undamaged hair bulb from the subcutaneous fatty tissue in which it is situated accordingly involves severing the hair shaft of the follicle at a point below the epidermis of skin surface, so as to leave the hair bulb intact and undamaged while still bearing a portion of the hair shaft.
Preferably, the hair shaft of the follicle is severed at the dermal-subcutaneous fat interface.
Any suitable cutting instrument can be employed to sever the hair shaft in this manner, but a keratotome or a scalpel are preferred.
The hair bulb with a hair shaft stump attached is then isolated from the skin by mechanically separating the hair from loosely adhering subcutaneous fat which normally surrounds the hair bulb. This is achieved after the dermis or upper layer of the skin has been separated and removed, to avoid damaging the hair bulb as it is pulled away.
The hair bulb together with hair shaft stump attached, is then transferred in an otherwise undamaged and fully functioning, viable state to a nutrient medium. Culture of the isolated hair follicle
The hair follicles isolated by the technique described herein are transferred to a suitable culture' medium for subsequent testing of substances that can then influence their future development.
The procedure now to be described represents a preferred method of culture and testing of hair growth.
In accordance with the preferred method of culture, isolated hair follicles, obtained from facelift skin are maintained in 1 ml of Williams E medium, supplemented with L-glutamine (2mM) , insulin (10 μg/ml) , hydrocortisone (lOng/ml) and antibiotics, either with or without a test hair growth substance (urea cycle intermediate) . The medium was incubated at 37°C in an atmosphere of 5% C02 + 95% air in individual wells of a 24 multiwell dish (Corning) , which permits detailed measurements to be made of the length of individual hair follicles.
Williams E medium is available from FLOW Laboratory under Catalogue No. 12-502. The formula of Williams E medium is described by Williams GM, et al., in Experimental Cell Research &9 (1971) on page 106.
Daily growth rate and cumulative growth for each follicle were calculated by measuring the change in length of the follicles each day using a microscope fitted with an eyepiece graticule and from this the average of all the follicles was calculated. Evaluation of Results
The response of an isolated hair follicle to a test substance, can accordingly be assessed by measuring the increase in length, if any, in the presence of a test substance against a control. The in vitro method described herein was used to assess the effect of three urea cycle intermediate, namely arginine hydrochloride, ornithine hydrochloride and citrulline, when used in the presence of- glutamine, compared with glutamine alone, to demonstrate the superiority of the urea cycle intermediates over glutamine alone.
The results obtained are summarised in the following Table 2 below.
Table 2
ω
09
2. q c m H ω m O
Notes on Table 2
1. Controls (without added urea cycle intermediate) .
2. Results based on observation on the growth of hai follicles taken from facelift skin of three patients. Fo each treatment, follicles from each patient were tested i accordance with the method described herein, making a tota of 18 treatments in all.
3. Results based on observation of growth of hair follicle taken from facelift skin from five patients. For eac treatment, follicles from each patient were tested i accordance with the method described herein, making a tota of 57 treatments for the control medium (glutamine alone) and 54 treatments for the medium supplement wit citrulline.
4. Not significant as calculated Student's t test.
The results summarised in Table 2 above indicate th significant increase in hair growth, as compared with glutamin alone (control) , that can be achieved with each of the urea cycl intermediates in the presence of glutamine, as promoters of th rate of hair growth. This confirms that urea cycle intermediate promote or at least maintain hair growth.
In a similar experiment, using Williams E medium as the control, and Williams E medium supplemented with 1mM arginine as the test medium, it was found that there was some variation in the percentage Increase in hair growth for follicles from three different patients. The percentages were 7%, 3.5% and 6% increase in hair growth compared to controls from the same patients. The average of 5.5% increase in hair growth was clearly statistically significant.
Like experiments was carried out using 1mM ornithine and 1mM citrilline as the supplement to the Williams E medium. The results with follicles from each patient were statistically significant and averaged 7.4% for citrulline and 6.4% for ornithine.
A test procedure for total protein synthesis utilised a similar culture of isolated follicles. The follicles were cultured in arginine-deficient Williams E medium supplemented so as to contain 0.287mM, 0.574mM or 1.435mM arginine, for two days. Incubation was then continued for a further three hours in the presence of 14C labelled leucine as well as the same concentration of arginine as before.
After incubation, the follicles were removed from the radioactive media, and washed with 3 x 1ml of PBS supplemented with lOmM unlabelled leucine, to displace non-covalently bound 1C-leucine. They were then homogenised in 1ml of ice-cold 0.1M K2EDTA, pH 12.3, in a hand-held glass/glass homogeniser. The homogenate was left at 4°C for 30 min. to release and dissolve the protein. Cell debris was removed by centrifugation, and HOμl samples of the supernatant removed for total protein determination by the Bio-Rad assay [based on Bradford, Anal.Biochem. , 72, 248 (1976)] . To the remaining supernatant was added 0.5ml of ice-cold 15% TCA, and this was left at 4°C for 15 min. to precipitate out the protein. The precipitate was collected, and washed with 4 x 5ml of 15% TCA, under vacuum onto Whatman GF/C (2.4cm) filters, which had been pre-washed with PBS supplemented with lOmM unlabelled leucine. Finally, the filters were dried and their radioactivity determined by liquid scintillation spectrometry. The cell debris was solubilised in 0.5ml of Soluene, and counting its radioactivity showed that less than 15% of incorporated radioactivity was discarded in the cell debris pellet. The results were:
Arginine concentration Leucine uptake (mM) (p ol/hour/follicle)
0 .287 80
0 . 574 93
1 .435 110
This showed that the arginine was enhancing protein synthesis in the hair follicles .
EXAMPLES
The invention is illustrated by the following examples, each of which provides a composition comprising one or more specific metabolic intermediates of the urea cycle or derivatives thereof in in accordance with the invention. Selected metabolic intermediates are indicated by the s tructure numbers l is ted earlier in this specif ication .
Example 1
This Example illustrates a lotion according to the invention which is suitable for topical application to the skin in order to enhance hair growth.
The lotion has the following formulation:
% w/w Intermediate (10) 1 ethanol 99 perfume q.s.
Example 2
This Example illustrates a hair tonic which is suitable for application to hair or scalp.
The hair tonic has the following formulation:
% w/w intermediate (11) 2 ethanol 49 water 49 perfume q.ε.
Example 3
This Example also illustrates a lotion which is suitable for topical application to the scalp.
The lotion has the following formulation:
% w/w Intermediate (12) 3 propan-2-ol 10 ethanol 87 perfume q.s. Example 4
This Example also illustrates a hair tonic which is suitable for application to hair or scalp.
The hair tonic has the following formulation:
% w/w Intermediate (13) 3 ethanol 40 water 57 perfume q.s.
Examples 5 to 8
The following formulations represent lotions which can be used topically in the treatment of bald or balding male or female heads.
w w
Examples 9 to 12
The following formulations represent creams which can b used in the treatment of baldness.
w/w
10 11 12
Cetyl alcohol polyoxyethylene (10) 4 4 4 4 Cetyl alcohol 4 4 4 4 Mineral oil 4 2 Paraffin wax 2 Intermediate (17) Intermediate (18) Intermediate (19) Intermediate (20) minoxidil Triethanolamine Butane-1,3-diol Xanthan gum Preservative Perfume Water
Example 13
This Example illustrates a water-in-oil high internal phas emulsion containing an amine according to the invention.
The emulsion consisted of 10% by volume oily phase and 90 by weight aqueous phase.
The oily phase and the aqueous phase had the followin constitution: % w/w
Oily phase
Sorbitan monooleate 20
Quaternium-18 hectorite 5
Liquid paraffin 75
The emulsion was prepared by taking 10 parts by volume of the oily phase and to it adding slowly with stirring 90 parts by volume of the aqueous phase.
The high internal phase water-in-oil emulsion so formed can be applied topically to the scalp, to improve hair growth and regrowth.
The following.two examples 14 and 15 illustrate shampoos for use in washing the hair and scalp, and for promoting hair growth on the scalp.
Example 14
w/w
Sodium lauryl ether sulphate (2 EO) [21% AD] 41.4 Lauryl dimethylamino acetic acid betaine: [30% AD] 4
Coconut fatty acid diethanola ine 1.5
Oleyl triethoxy phosphate (BRIPHOS 03D) 1 Polyglycol-polyamine condensation resin (POLYQUART H) [50% active] 1.5
Preservative, colouring matter, salt 0.58 Intermediate (22) 10
Perfume q.s.
Water to 100
Example 15
w w
This Example also illustrates a lotion which is suitable fo topical application to the scalp.
The lotion has the following formulation:
w/w Intermediate (24) 5 minoxidil 1 propan-2-ol 10 ethanol 84
Example 17
This example illustrates a powder composition according t the invention which can be applied topically to the scalp.
% w/w
Chemically modified starch 5
Chemically modified cellulose - Boric acid 10
Zinc oxide 5.
Intermediate (25) 3
Minoxidil 5
Perfume q.s.
Chalk 10
Talc to 100
Example 18
The following example illustrates a lotion according to th invention which can be applied topically to the scalp to preven hair loss and stimulate hair regrowth.
w/w
Intermediate (26) 7 glucaro-l,4-lactone 2 ethanol 16 citric acid 1.05 water to 100
pH adjusted to 4.2 with sodium hydroxide
Examples 19 and 20
These examples illustrate hair tonics which are suitable fo application to the hair and scalp.
The hair tonics had the following formulation:
w/w
19 20
Intermediate (27) 2 Intermediate (28) 2 glucaro-l,5-lactarc 3 3 ethanol 50 50 water 45 45 Example 21
This example illustrates a shampoo which is suitable for topical application to hair in order to cleanse it, at the same time delivering a metabolic intermediate to the scalp to enhance hair growth or regrowth.
The shampoo had the following formulation:
% w/w Triethanolamine lauryl sulphate 16.8
Coconut diethanolamide 3.0 Hydroxypropylmethyl- cellulose (1) 0.25
Corn syrup (80% solids) (2) 20.5 Dimethylpolysiloxane (3) 1.0
Cationic cellulose (4) 0.5
Ethyl alcohol (SDA 40) 9.0 Vinyl carboxy polymer (5) 0.75
Intermediate (29) 8
Perfume, colour, preservative q.s. Water to 100
Acid or base to pH: 6.5
1 - Methocel E4M (Dow Chemical) 2 - 42 Dextrose equivalent (Staley 1300)
3 - 60,000 centistokes (Viscasil, GEC)
4 - Polymer JR 400 5 - Carbopol 941 (BF Goodrich)
Example 22
This example illustrates a shampoo in accordance with the invention. The shampoo had the following formulation:
% w/w Sodium lauryl ether sulphate (3EO) 10
Pearlising agent 4
Betaine 2
Cationic polymer 0.2
Intermediate (30) 6.5 minor ingredients 4 water to 100
pH value 6 to 7
viscosity: 3500 to 4000 cps (Brookfield Spindle No. 3 at 10 rpm 25°C)
Example 23
This example illustrates a shampoo in accordance with this invention.
The shampoo had the following formulation:
% w w
pH value 6. 5
viscosity: 5000 cps (Brookfield Spindle No. 3 at 10 rpm, 25°C)
Example 24
This example illustrates a shampoo in accordance with this invention.
The shampoo had the following formulation:
% w w
pH value 6.5
viscosity: 5000 cps (Brookfield Spindle No. 3 at 10 rpm, 25°C)
The following examples 25 and 26 illustrate shampoos for use in washing the hair and scalp, and for promoting hair growth on the scalp. Example 25
% w/w Sodium lauryl ether sulphate (2 EO) [21% AD] 41.4
Lauryl dimethylamino acetic acid betaine: [30% AD] Coconut fatty acid diethanolamine Oleyl triethoxy phosphate (BRIPHOS 03D) Polyglycol-polyamine condensation resin (POLYQUART H) [50% active] Preservative, colouring matter, salt Intermediate (33) Perfume Water
Exam le 26
Example 27
This Example also illustrates a lotion which is suitable for topical application to the scalp.
The lotion has the following formulation: w/w
Intermediate (35) 5 minoxidil 1 propan-2-ol 10 ethanol 84
Example 28
This example illustrates a powder composition according t the invention which can be applied topically to the scalp.
% w/w
Chemically modified starch 5 Chemically modified cellulose Boric acid 10
Zinc oxide 5
Intermediate (36) 3
Minoxidil 5
Perf me q.s. Chalk 10
Talc to 100
Example 29
The following example illustrates a lotion according to th invention which can be applied topically to the scalp to preven hair loss and stimulate hair regrowth.
w w
Example 30
This example illustrates a shampoo which is suitable for topical application to hair in order to cleanse it, at the same time delivering a metabolic intermediate to the scalp to enhance hair growth or regrowth.
The shampoo had the following formulation:
% w/w Triethanolamine lauryl sulphate 16.8 Coconut diethanolamide 3.0
Hydroxypropylmethy1- cellulose (1) 0.25
Corn syrup (80% solids) (2) 20.5 Dimethylpolysiloxane (3) 1.0
Cationic cellulose (4) 0.5
Ethyl alcohol (SDA 40) 9.0 Vinyl carboxy polymer (5) 0.75
Intermediate (38) 8
Perfume, colour, preservative q.s.
Water to 100
Acid or base to pH: 6.5
1 - Methocel E4M (Dow Chemical) 2 - 42 Dextrose equivalent (Staley 1300) 3 - 60,000 centistokes (Viscasil, GEC) 4 - Polymer JR 400
5 - Carbopol 941 (BF Goodrich)
Example 31
This example illustrates a shampoo in accordance with th invention. Firstly a pre-emulsion of polyisobutylene was made by mixing at room temperature the following ingredients in a Winkworth twin-Z-blade mixer (model MZ150) .
Pre-emulsion ingredient % w/w
Vistanex1 58
Alipal C0-4332 1.4
Water 40.6
(1) Polyisobutylene, approx molecular weight 60,000, ex Exxon. (2) Sodium alkyl phenyl polyethox lene sulphate.
The pre-emulsion was then mixed, with stirring, with the additional ingredients of . the shampoo. to give a final composition as follows:
Ingredient
Pre-emulsion
Sodium lauryl ether sulphate 2E0 Cocoamidopropylbetaine
Euperlan PK900<3)
Jaguar C13s(
Citrulline
Formalin BY 22-026( )
NaCl
Perfume, colouring
Water
(3) Mixture of triethylene glycol distearate and SLES 2EO, ex Henkel.
(4) Guar hydroxypropyl trimonium chloride, ex Meyhall.
(5) Polydimethylsiloxane, 50% aqueous emulsion, ex Tora Silicone. Example 32
SLES 2E0 Cocoamidopropyl betaine Silicone emulsion(1) Jaguar C13s
Ornithine hydrochloride Ethylene glycol distearate Octopirox(2)
Preservative, Colour, Perfume Water
(1) BY22-026 ex Toray Silicone Co Ltd comprising: % w/w Lauryl alcohol ethoxylate 2E0 2
Lauryl alcohol ethoxylate 21EO 2
Polydimethylsiloxane (60,000 cS) 50 Preservative qs Water to 100
(2) Piroctone olamine ex Hoechst.
The shampoo is prepared using a simple hot process whereby all the ingredients except perfume are mixed at 70°C using a paddle stirrer. The mixture is then cooled slowly, and perfume added below 40°C.
Example 33 % w/w Ammonium lauryl sulphate/
Ammonium lauryl ether sulphate 8
Cocodiethanolamide 3
Arginine hydrochloride 5.5 Ionol butyl hydroxytoluene (BHT) 0.05
BRIPHOS 03Dα) 1.05
Hydrolised silk protein 0.1 CARBOPOL 1342<2) 0.4
Polyethoxylated lanolin 0.3
JAGUAR C13s 0.3
TIMIRON MP-1005(3) 0.06 Triethanolamine 0.8
Silicone emulsion (50%)<4) 6
Perfume, Preservative qs
Water to 100
(1) A mixture of esters of phosphoric acid and the polyethylene glycol ether of oleyl alcohol.
(2) A copolymer of a carboxylic acid containing monomer and acrylic esters ex Goodrich.
(3) Titanium dioxide coated mica ex Merck.
(4) Silicone emulsion comprises 50% by weight silicone oil (60,000 cs) , 4% by weight cetostearyl alcohol and 25% by weight SLES 2E0.
The ammonium lauryl sulphate/ammonium lauryl ether sulphate and the BHT were heated in the main vessel to 75°C to melt the BHT, with constant stirring.
CARBOPOL 1342 was dispersed with stirring in 50% of the water, and the resulting dispersion added to the main vessel.

Claims

CLAIMS:
1. Use for increasing, enhancing or maintaining
mammalian hair growth, following topical application, of a composition which comprises
(i) an effective amount of a metabolic intermediate of the urea cycle selected from the group consisting of the amino acids arginine, ornithine, citrulline and arginosuccinate, ester, alkyl, acyl, phosphatyl and peptide derivatives of said amino acids and salts and hydrosalts of said aminoacids and derivatives thereof, and
(ii) a cosmetically acceptable vehicle for said metabolic intermediate.
2. Use according to claim 1 wherein the metabolic intermediate is selected from the group consisting of arginine, said derivatives of arginine, and salts and hydrosalts thereof.
3. Use according to claim 2 wherein the metabolic intermediate is selected from L-arginine and L-arginine hydrochloride.
4. Use according to claim 1 wherein the metabolic intermediate is selected from the group consisting of ornithine, said derivatives of ornithine, and salts and hydrosalts thereof.
5. Use according to claim 1 wherein the metabolic intermediate is selected from the group consisting of citrulline, said derivatives of citrulline, and salts and hydrosalts thereof.
6. Use according to claim 1 wherein the metabolic intermediate is selected from the group consisting of arginosuccinate, said derivatives of arginosuccinate, and salts and hydrosalts thereof.
7. Use according to claim 1, wherein the metabolic intermediate is chosen from: arginine hydrochloride
ornithine hydrochloride
sodium arginate
arginine phosphate, sodium salt
sodium arginosuccinate
potassium arginosuccinate
L-α-alanylarginine hydrochloride
L-cystinylornithine
L-methionylcitrulline
L-arginylarginine
L-ornithylcitrulline
L-glutaminylarginine
L-glutaminylcitrulline
L-tyrosinylarginine
L-arginylmethionine
L-ornithylmethionine
L-citrullylmethionine
L-arginylaspartate
L-arginylglutamate
L-arginylleucine acetate salt
L-arginyllysine acetate salt
L-arginylphenylalanine acetate salt
L-ornithylaspartate
methylarginine dihydrochloride
arginine ethyl ester dihydrochloride
ethylcitrulline
n-propylornithine
n-octylarginine
n-octylcitrulline
n-octylornithine
8. Use according to any one of claims 1 to 7 wherein the composition contains from 0.01 to 30% by weight of said metabolic intermediate.
9. Use according to any one of claims 1 to 8 wherein the composition contains not more than 4% by weight of
surfactant.
10. Use according to any one of claims 1 to 8 wherein the composition contains at least 4% by weight of surfactant and more than 5% by weight of said metabolic intermediate or derivative thereof.
11. Use according to any one of claims 1 to 10 by topical application to the bald or balding human scalp.
12. A composition according to claim 11 wherein the metabolic intermediate is selected from the group
consisting of arginine, said derivatives of arginine, and salts and hydrosalts thereof.
13. A composition according to claim 12 wherein the metabolic intermediate is selected from L-arginine and L-arginine hydrochloride.
14. A composition according to claim 11 wherein the metabolic intermediate is selected from the group
consisting of ornithine, said derivatives of ornithine, and salts and hydrosalts thereof.
15. A composition according to claim 11 wherein the metabolic intermediate is selected from the group
consisting of citrulline, said derivatives of citrulline, and salts and hydrosalts thereof.
16. A composition according to claim 11 wherein the metabolic intermediate is selected from the group consisting of arginosuccinate, said derivatives of arginosuccinate, and salts and hydrosalts thereof.
17. A composition according to claim 11, wherein the metabolic intermediate is chosen from: arginine hydrochloride
ornithine hydrochloride
sodium arginate
arginine phosphate, sodium salt sodium arginosuccinate
potassium arginosuccinate
L-α-alanylarginine hydrochloride
L-cystinylornithine
L-methionylcitrulline
L-arginylarginine
L-ornithylcitrulline
L-glutaminylarginine
L-glutaminylcitrul1ine
L-tyrosinylarginine
L-arginylmethionine
L-ornithylmethionine
L-citrullylmethionine
L-arginylaspartate
L-arginylglutamate
L-arginylleucine acetate salt
L-arginyllysine acetate salt
L-arginylphenylalanine acetate salt
L-ornithylaspartate
methylarginine dihydrochloride
arginine ethyl ester dihydrochloride
ethylcitrulline
n-propylornithine
n-octylarginine
n-octylcitrulline
n-octylornithine
18. A composition according to claim 11 in which the intermediate forms from 0.01 to 30% by weight of the composition.
EP93923626A 1992-10-30 1993-10-27 Cosmetic composition Withdrawn EP0666729A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9222772 1992-10-30
GB929222772A GB9222772D0 (en) 1992-10-30 1992-10-30 Cosmetic composition
PCT/GB1993/002210 WO1994009750A1 (en) 1992-10-30 1993-10-27 Cosmetic composition

Publications (1)

Publication Number Publication Date
EP0666729A1 true EP0666729A1 (en) 1995-08-16

Family

ID=10724275

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93923626A Withdrawn EP0666729A1 (en) 1992-10-30 1993-10-27 Cosmetic composition

Country Status (10)

Country Link
EP (1) EP0666729A1 (en)
JP (1) JPH08502509A (en)
KR (1) KR950703926A (en)
CN (1) CN1091952A (en)
AU (1) AU5342694A (en)
CA (1) CA2146348A1 (en)
GB (1) GB9222772D0 (en)
TW (1) TW262384B (en)
WO (1) WO1994009750A1 (en)
ZA (1) ZA938000B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19520662A1 (en) * 1995-06-07 1996-12-12 Beiersdorf Ag Treatment for dandruff and hair
JPH09278630A (en) * 1996-02-15 1997-10-28 Kao Corp Hair cosmetic
WO1998007744A1 (en) * 1996-08-23 1998-02-26 Sederma S.A. Synthetic peptides and their use in cosmetic or dermopharmaceutical compositions
TW505521B (en) * 1997-06-25 2002-10-11 Kao Corp Hair cosmetics
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
JPH11279040A (en) * 1998-03-27 1999-10-12 Kao Corp Composition for external use for skin
GB9811754D0 (en) * 1998-06-01 1998-07-29 Unilever Plc Hair treatment compositions
FR2786693B1 (en) * 1998-12-04 2003-01-17 Dior Christian Parfums COSMETIC AGENT TO OBTAIN A SLIMMING ACTION
AU2459100A (en) * 1999-02-10 2000-08-29 Taisho Pharmaceutical Co., Ltd. Hair growth stimulants and method for screening substance having hair growth stimulating effect
DE29906038U1 (en) * 1999-04-01 1999-07-15 Maindok Hair tonic
GB9917453D0 (en) 1999-07-23 1999-09-29 Unilever Plc Method of hair treatment using organic amino compounds
GB9917452D0 (en) 1999-07-23 1999-09-29 Unilever Plc Method of hair treatment using organic amino compounds
ES2429443T3 (en) 2004-04-19 2013-11-14 Strategic Science & Technologies, Llc Transdermal supply of beneficial substances by means of an environment of high ionic strength
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
FR2894142B1 (en) * 2005-12-05 2009-06-12 Oreal USE OF THE TYROSINE-ARGININE DIPEPTIDE AND NIACIMANIDE ASSOCIATION AS A P-SUBSTANCE ANAGONIST
US8858968B2 (en) 2005-12-05 2014-10-14 L'oreal Use of tyrosine-arginine dipeptide and niacinamide as substance P antagonist
ES2612269T3 (en) * 2006-06-08 2017-05-16 Ajinomoto Co., Inc. Composition for hair growth
BRPI0811790B1 (en) * 2007-07-03 2016-08-30 Unilever Nv "non-permanent hair shaping composition and non-permanent hair shaping method"
EP2033623A1 (en) * 2007-09-07 2009-03-11 Cutech S.R.L. Compositions comprising ornithine ketoglutarate (OKG)
FR2929118B1 (en) * 2008-03-28 2010-05-07 Oreal USE OF THE ASSOCIATION OF MADECASSOSIDE AND / OR TERMINOLOSIDE AND ARGININE TO INDUCE AND / OR STIMULATE THE GROWTH OF HUMAN KERATIN FIBERS AND / OR BRAKE THEIR FALL
FR2943253B1 (en) * 2009-03-20 2011-04-22 Oreal COMPOSITION CONTAINING THE ASSOCIATION OF MADECASSOSIDE, ARGININE AND POLYSORBATE
US9072659B2 (en) 2009-06-24 2015-07-07 Strategic Science & Technologies, Llc Topical composition containing naproxen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
KR101643797B1 (en) 2009-06-24 2016-07-28 스트러티직 사이언스 앤드 테크놀로지스, 엘엘씨 Topical composition containing ibuprofen
CN102526250A (en) * 2010-12-24 2012-07-04 漆又毛 Application of composition of amino acids and extracts in preparation of drugs with function of improving memory
JP2014501283A (en) 2010-12-29 2014-01-20 ストラテジック サイエンス アンド テクノロジーズ, エルエルシー Systems and methods for the treatment of allergies and other indications
JP2014504592A (en) 2010-12-29 2014-02-24 ストラテジック サイエンス アンド テクノロジーズ, エルエルシー Treatment of erectile dysfunction and other indications
US9700504B2 (en) * 2012-06-19 2017-07-11 Debraj Shome Composition and method for an intradermal hair growth solution
WO2014061728A1 (en) * 2012-10-17 2014-04-24 味の素株式会社 Cosmetic composition
JP6115086B2 (en) * 2012-11-13 2017-04-19 味の素株式会社 Cosmetic composition containing acetate of amino acid compound
EP3062766A1 (en) 2013-10-29 2016-09-07 L'Oreal, S.A. Use of mono ornithine ketoglutarate (mokg)
FR3022778A1 (en) * 2014-06-30 2016-01-01 Oreal USE OF A COMBINATION OF ORNITHINE AND CITRIC ACID TO LIMIT HAIR LOSS
CN109475483B (en) * 2016-03-24 2022-06-14 凯塞尔德国有限公司 Aspartyl dipeptides for skin care and cosmetic use
CN107573404B (en) * 2017-09-22 2022-04-12 南京优科生物医药研究有限公司 Active salt of dipeptide compound of ornithine and aspartate and application thereof
JP7169623B2 (en) * 2018-02-14 2022-11-11 株式会社 リトル・サイエンティスト Cosmetic containing arginine ester
EP4129409A4 (en) 2020-03-26 2024-05-01 Ajinomoto Co., Inc. Composition for promoting hair thickening, composition for sustaining growth phase in hair cycle and composition for promoting vegf production, composition for promoting transition from resting phase to growth phase in hair cycle and composition for promoting fgf7 production, and composition for promoting hair cycle normalization

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL120093C (en) * 1958-07-24
DE3118882C2 (en) * 1981-05-13 1985-11-14 Rudolf V. Dr.rer.nat Dipl.-Chem. 5024 Pulheim Noronha Hair loss and hair growth agents
JPS59196809A (en) * 1983-04-22 1984-11-08 Lion Corp Hair cosmetic composition
JPS61151109A (en) * 1984-12-26 1986-07-09 Lion Corp Hair treatment composition
JPS61246130A (en) * 1985-04-24 1986-11-01 Japan Fine Chem Kk External agent for stimulation skin cell activity
JPH01242517A (en) * 1988-03-25 1989-09-27 Ajinomoto Co Inc Hair cosmetic composition
FR2669224B1 (en) * 1990-11-15 1995-04-28 Marcel Contier HAIR COMPOSITIONS, IN PARTICULAR FOR THE NEUTRALIZATION OF LACTIC ACID FROM SCALP AND METHOD OF COSMETIC TREATMENT OF SCALP.
JPH04308523A (en) * 1991-04-04 1992-10-30 Kanebo Ltd Hair-tonic cosmetic
DE4205931A1 (en) * 1992-02-20 1993-08-26 Maindok Friedrich Use of infusion soln. of electrolyte concentrate of arginine hydrochloride - prevents hair fallout and promotes hair growth
GB9210768D0 (en) * 1992-05-20 1992-07-08 Unilever Plc Cosmetic composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9409750A1 *

Also Published As

Publication number Publication date
KR950703926A (en) 1995-11-17
AU5342694A (en) 1994-05-24
WO1994009750A1 (en) 1994-05-11
JPH08502509A (en) 1996-03-19
TW262384B (en) 1995-11-11
GB9222772D0 (en) 1992-12-09
CA2146348A1 (en) 1994-05-11
ZA938000B (en) 1995-04-28
CN1091952A (en) 1994-09-14

Similar Documents

Publication Publication Date Title
EP0666729A1 (en) Cosmetic composition
US5559092A (en) Cosmetic composition
EP0532219B1 (en) Cosmetic composition
US8632759B2 (en) Hair restorer
JP2001517688A (en) Use of ellagic acid and its derivatives in cosmetics and dermatology
KR20000069083A (en) Composition containing an antifungal and a cationic agent
JPH0363213A (en) Cosmetic compound
JPS62226917A (en) Skin treatment composition
JPH0445486B2 (en)
US6184252B1 (en) 2-amino-1,3-alkanediol compositions for inducing/stimulating hair growth and/or retarding hair loss
CA2096506C (en) Cosmetic composition
EP0580409A2 (en) Cosmetic composition containing DOPA derivatives
KR970001642B1 (en) Cosmetic composition
JP3644809B2 (en) External preparation for head
KR20000022127A (en) Scalp care compositions
JPH03112912A (en) Cosmetic composition
JP3505003B2 (en) External preparation
JP2002037716A (en) Kaurenes-containing composition, hair-growing agent and skin care agent
JP3542700B2 (en) Head composition
JP3496896B2 (en) Hair restorer and hair cosmetic
FR2764504A1 (en) Use of a lipid-free milk product
EP2861205B1 (en) Composition including a pyridine dicarboxylic acid ester and a glucose and fatty acid ester.
JPH09227328A (en) Cosmetics

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950401

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE ES FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 19960122

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960604